Abstract:Hypoxia is a hallmark of solid tumors. Hypoxic cancer cells adjust their metabolic characteristics to regulate the production of cellular reactive oxygen species (ROS) and facilitate ROS‐mediated metastasis. Peroxisome proliferator‐activated receptor γ (PPARγ) is a nuclear receptor that regulates the transcription of fatty acid metabolism‐related genes that have a key role in the survival and proliferation function of hypoxic cancer cells. In the present study, mRNA expression in HepG2 cells under chemically induced hypoxia was assessed. The protein expression levels of hypoxia‐inducible factor 1α (HIF‐1α) were measured using western blotting. Following treatment with the PPARγ agonist pioglitazone, cell viability was assessed using a Cell Counting Kit‐8 assay, whilst cell proliferation and death were determined using 5‐ethynyl‐2'‐deoxyuridine incorporation staining, and calcein‐acetoxymethyl ester and propidium iodide staining, respectively. Cellular ROS production was assessed using dihydroethidium staining. Cobalt chloride was used to induce hypoxia in HepG2 cells, which was evaluated using HIF‐1α expression. The results revealed that the mRNA expression of PPARγ, CD36, acetyl‐co‐enzyme A dehydrogenase (ACAD) medium chain (ACADM) and ACAD short‐chain (ACADS) was downregulated in hypoxic HepG2 cells. The PPARγ agonist pioglitazone decreased the cell viability of hypoxic HepG2 cells by inhibiting cell proliferation and inducing cell death. Following treatment with the PPARγ agonist pioglitazone, hypoxic HepG2 cells produced excessive ROS. ROS‐mediated cell death induced by the PPARγ agonist pioglitazone was rescued with the antioxidant N‐acetyl‐L‐cysteine. The downregulated mRNA expression of PPARγ, CD36, ACADM and ACADS was not reverted by a PPARγ agonist in hypoxic HepG2 cells. By contrast, the PPARγ agonist suppressed the mRNA expression of BCL2, which was upregulated in hypoxic HepG2 cells. In summary, the PPARγ agonist stimulated excessive ROS production to inhibit cell proliferation and increase the death of hypoxic HepG2 cells by decreasing BCL2 mRNA expression, suggesting a negative association between PPARγ and BCL2 in the regulation of ROS production in hypoxic HepG2 cells.

Inhibition of Cancer Cell Proliferation by PPARγ is Mediated by a Metabolic Switch That Increases Reactive Oxygen Species Levels.

Pioglitazone, a peroxisome proliferator‐activated receptor γ agonist, induces cell death and inhibits the proliferation of hypoxic HepG2 cells by promoting excessive production of reactive oxygen species

Dual PPARγ/ɑ agonist oroxyloside suppresses cell cycle progression by glycolipid metabolism switch-mediated increase of reactive oxygen species levels

Selective activation of PPARgamma in breast, colon, and lung cancer cell lines

Peroxisomes and PPARs: Emerging role as master regulators of cancer metabolism

Role of Peroxisome Proliferator-Activated Receptor α-Dependent Mitochondrial Metabolism in Ovarian Cancer Stem Cells

PPARγ Accelerates Cellular Senescence by Inducing P16ink4α Expression in Human Diploid Fibroblasts

Peroxisome Proliferator-Activated Receptors (PPARs) and Oxidative Stress in Physiological Conditions and in Cancer

O-GlcNAcylation of G6PD Promotes the Pentose Phosphate Pathway and Tumor Growth

Peroxisome Proliferator-Activated Receptor Γ and Colorectal Cancer.

Peroxisome proliferator-activated receptors: Key regulators of tumor progression and growth

Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells

The Inhibition of the Breast Cancer by PPARγ Agonist Pioglitazone Through JAK2/STAT3 Pathway.

PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.

Targeting Peroxisome Proliferator-Activated Receptor-β/δ, Reactive Oxygen Species and Redox Signaling with Phytocompounds for Cancer Therapy

PPARγ/SOD2 Protects Against Mitochondrial ROS-Dependent Apoptosis via Inhibiting ATG4D-Mediated Mitophagy to Promote Pancreatic Cancer Proliferation

PPAR-γ Modulators as Current and Potential Cancer Treatments

Prostaglandin 15d-PGJ2 inhibits proliferation of lung adenocarcinoma cells by inducing ROS production and activation of apoptosis via sirtuin-1

Regulatory Role of KEAP1 and NRF2 in PPARγ Expression and Chemoresistance in Human Non-Small-cell Lung Carcinoma Cells.

Activation of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) inhibits human breast cancer cell line tumorigenicity

The role of peroxisome proliferator-activated receptor gamma in prostate cancer